LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Davies, EC; Chandler, CIR; Innocent, SHS; Kalumuna, C; Terlouw, DJ; Lalloo, DG; Staedke, SG; Haaland, A (2012)
Publisher: Public Library of Science
Journal: PLoS ONE
Languages: English
Types: Article
Subjects: Global Health, Social and Behavioral Sciences, Research Article, Infectious Diseases, Sociology, qv_256, wa_395, Medicine, qv_38, Q, R, wc_770, Drugs and Devices, Science, Parasitic Diseases, Public Health
The wide-scale roll-out of artemisinin combination therapies (ACTs) for the treatment of malaria should be accompanied by continued surveillance of their safety. Post-marketing pharmacovigilance (PV) relies on adverse event (AE) reporting by clinicians, but as a large proportion of treatments are provided by non-clinicians in low-resource settings, the effectiveness of such PV systems is limited. To facilitate reporting, AE forms should be easily completed; however, most are challenging for lower-level health workers and non-clinicians to complete. Through participatory research, we sought to develop user-friendly AE report forms to capture information on events associated with ACTs.\ud \ud Following situation analysis, we undertook workshops with community medicine distributors and health workers in Jinja, Uganda, to develop a reporting form based on experiences and needs of users, and communication and visual perception principles. Participants gave feedback for revisions of subsequent versions. We then conducted 8 pretesting sessions with 77 potential end users to test and refine passive and active versions of the form.\ud \ud The development process resulted in a form that included a pictorial storyboard to communicate the rationale for the information needed and facilitate rapport between the reporter and the respondent, and a diary format to record the drug administration and event details in chronological relation to each other. Successive rounds of pretesting used qualitative and quantitative feedback to refine the form, with the final round showing over 80% of the form completed correctly by potential end users.\ud \ud We developed novel AE report forms that can be used by non-clinicians to capture pharmacovigilance data for anti-malarial drugs. The participatory approach was effective for developing forms that are intuitive for reporters, and motivating for respondents. The forms, or their key components, could be adapted for use in other low-literacy settings to improve quality and quantity of drug safety reports as new medicines are scaled-up.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Talisuna AO, Staedke SG, D'Alessandro U (2006) Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J 5: 50.
    • 2. Stergachis A, Bartlein RJ, Dodoo A, Nwokike J, Kachur SP (2010) A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals. Malar J 9: 148.
    • 3. Kuemmerle A, Dodoo AN, Olsson S, Van Erps J, Burri C, et al. (2011) Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J 10: 57.
    • 4. European Medicines Agency (1995) ICH Topic E 2 A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Available: http://www.emea.europa.eu/pdfs/human/ich/037795en.pdf. Accessed 2011 Apr 29.
    • 5. Medicines and Healthcare Products Regulatory Agency Yellow Card Scheme. Available: http://yellowcard.mhra.gov.uk/the-yellow-card-scheme/. Accessed 2011 Apr 30.
    • 6. Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, et al. (2008) Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health.
    • 7. Etkin NL (1992) Side-Effects - Cultural Constructions and Reinterpretations of Western Pharmaceuticals. Medical Anthropology Quarterly 6: 99-113.
    • 8. Kamat VR (2009) Cultural interpretations of the efficacy and side effects of antimalarials in Tanzania. Anthropology & Medicine 16: 293-305.
    • 9. Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, et al. (2008) Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J 7: 107.
    • 10. Mehta U, Durrheim D, Mabuza A, Blumberg L, Allen E, et al. (2007) Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa. Drug Saf 30: 899-910.
    • 11. Cornwall A, Jewkes R (1995) What is participatory research? Soc Sci Med 41: 1667-1676.
    • 12. Haaland A (1984) Pretesting communication materials with special emphasis on child health and nutrition education: a manual for trainers and supervisors. Rangoon, Burma: UNICEF.
    • 13. Chetley A, Hardon A, Hodgkin A, Haaland A, Fresle D (2007) How to Improve the Use of Medicines by Consumers. Geneva: World Health Organisation.
    • 14. Haaland A, Molyneux CS, Marsh V (2006) Quality information in field research: Training manual on practical communication skills for field researchers and project personnel. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases. Available: http://whqlibdoc.who.int/hq/2006/TDR_IRM_PCT_05.1_eng. pdf. Accessed 2012 Feb 04.
    • 15. Van der Geest S, Whyte SR (1989) The Charm of Medicines: Metaphors and Metonyms. Medical Anthropology Quarterly 3: 345-367.
    • 16. Haaland A (2001) Reporting with Pictures. A concept paper for researchers and health policy decision-makers. Geneva: UNDP/WOrld Bank/WHO Special Programme for Research and Training in Tropical Diseases.
    • 17. Charles C, Gafni A, Whelan T (1999) Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 49: 651-661.
    • 18. Mead N, Bower P (2000) Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med 51: 1087-1110.
    • 19. Ajayi IO, Oladepo O, Falade CO, Bamgboye EA, Kale O (2008) The development of a treatment guideline for childhood malaria in rural Southwest Nigeria using participatory approach. Patient Educ Couns.
    • 20. UNDP/World Bank/WHO (1996) Community Directed Treatment with ivermectin. Report of a Multi-Country study. Special Programme for Research and Training in Tropical Diseases (TDR) in collaboration with the Onchocerciasis Control Programme in West Africa (OCP) and the African Programme for Onchocerciasis Control (APOC).
    • 21. World Health Organisation (2007) A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva. Available: http://www.who.int/ m e d i c i n e s / a r e a s / q u a l i t y _ s a f e t y / s a f e t y _ e f f i c a c y / h a n d b o o k _ antimalarialpharmvigilance.pdf. Accessed 2011 Apr 30.
    • 22. Edwards IR (2008) Controlled trials and risk of harm. Drug Saf 31: 961-963.
    • 23. WHO, MMV (2009) Pharmacovigilance guidance for countries participating in AMFm Phase 1. WHO-MMV joint technical consultation on active pharmacovigilance monitoring with a special focus on AMFm. Geneva: World Health Organisation & Medicines for Malaria Venture.
    • 24. Blenkinsopp A, Wilkie P, Wang M, Routledge PA (2007) Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 63: 148-156.
    • 25. Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362: 865-869.
    • 26. Oshikoya KA, Senbanjo IO, Njokanma OF (2009) Parental reporting of suspected adverse drug reactions in children in Lagos, Nigeria. Arch Dis Child 94: 469-473.
    • 27. Mehta U, Allen E, Barnes KI (2010) Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria. Expert Rev Clin Pharmacol 3: 509-525.
    • 28. Bhattacharyya K, Winch P, LeBan K, Tien M (2001) Community Health Worker Incentives and Disincentives: How They Affect Motivation, Retention, and Sustainability. Arlington, Virginia: Published by the Basic Support for Institutionalizing Child Survival Project (BASICS II) for USAID.
    • 29. Rowe SY, Olewe MA, Kleinbaum DG, McGowan JE, Jr., McFarland DA, et al. (2007) Longitudinal analysis of community health workers' adherence to treatment guidelines, Siaya, Kenya, 1997-2002. Trop Med Int Health 12: 651-663.
    • 30. Kelly JM, Osamba B, Garg RM, Hamel MJ, Lewis JJ, et al. (2001) Community health worker performance in the management of multiple childhood illnesses: Siaya District, Kenya, 1997-2001. Am J Public Health 91: 1617-1624.
    • 31. Das J, Hammer J, Sanchez-Paramo C (2011) The Impact of Recall Periods on Reported Morbidity and Health Seeking Behaviour. World Bank, Development Research Group.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article